What is Sensei Biotherapeutics, Inc.'s earnings per share (EPS)?

Sensei Biotherapeutics, Inc. (SNSE) reported diluted earnings per share of $-16.72 for fiscal year 2025. This represents a 30.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sensei Biotherapeutics, Inc. Financials

SNSE

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows Sensei Biotherapeutics, Inc. (SNSE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SNSE FY2025 2026-05-15

Sensei's financials show a cash-runway business: operating losses are narrowing, but they still turn almost entirely into cash burn.

From FY2022 to FY2025, net loss improved from -$48.6M to -$21.1M, yet operating cash flow in FY2025 was still -$20.5M; because capex was only $16K, better accounting results have not changed the core fact that day-to-day operations consume cash almost dollar for dollar.

The balance sheet is lightly levered: total liabilities were just $4.3M against $18.6M of equity, and the current ratio stayed at 5.1x. That means near-term bills are manageable, so the real constraint is liquidity runway, not debt service.

Even with cost cutting, the company is shrinking with its cash pool: total assets fell from $74.4M in FY2023 to $22.9M in FY2025 while selling, general and admin expense dropped from $18.8M to $11.3M. The business looks asset-light but funding-dependent, more like an operating burn model than a reinvestment-heavy one.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Sensei Biotherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Sensei Biotherapeutics, Inc. carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.06, Sensei Biotherapeutics, Inc. holds $5.06 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Sensei Biotherapeutics, Inc. generates a -113.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -78.6% the prior year.

Piotroski F-Score Weak

1/9

Sensei Biotherapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.97x

For every $1 of reported earnings, Sensei Biotherapeutics, Inc. generates $0.97 in operating cash flow (-$20.5M OCF vs -$21.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-696.5x

Sensei Biotherapeutics, Inc. earns $-696.5 in operating income for every $1 of interest expense (-$22.3M vs $32K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$22.2M

YoY+30.9%

Sensei Biotherapeutics, Inc.'s EBITDA was -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.9% from the prior year.

Net Income

-$21.1M

YoY+30.1%

Sensei Biotherapeutics, Inc. reported -$21.1M in net income in fiscal year 2025. This represents an increase of 30.1% from the prior year.

EPS (Diluted)

$-16.72

YoY+30.4%

Sensei Biotherapeutics, Inc. earned $-16.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 30.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$20.5M

YoY+17.5%

Sensei Biotherapeutics, Inc. generated -$20.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 17.5% from the prior year.

Cash & Debt

$8.7M

YoY-13.3%

5Y CAGR-12.2%

Sensei Biotherapeutics, Inc. held $8.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.2%

Sensei Biotherapeutics, Inc. had 1M shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-113.4%

YoY-34.9pp

Sensei Biotherapeutics, Inc.'s ROE was -113.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 34.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$16K

YoY-89.0%

5Y CAGR-57.9%

Sensei Biotherapeutics, Inc. invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.0% from the prior year.

SNSE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$11.3M-13.1%	$13.0M-30.5%	$18.8M-5.3%	$19.8M+25.2%	$15.8M+110.1%	$7.5M
Operating Income	-$22.3M+31.7%	-$32.6M+12.0%	-$37.1M+26.1%	-$50.2M-33.9%	-$37.5M-92.7%	-$19.5M
Interest Expense	$32K-64.4%	$90K-37.5%	$144K-34.2%	$219K-67.3%	$670K-60.3%	$1.7M
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	-$21.1M+30.1%	-$30.2M+11.6%	-$34.1M+29.8%	-$48.6M-32.1%	-$36.8M-83.1%	-$20.1M
EPS (Diluted)	$-16.72+30.4%	$-24.01	$-1.22+22.8%	$-1.58-18.8%	$-1.33	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$100K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$19.7M	N/A	$2.3M-13.4%	$2.7M-24.7%	$3.5M	N/A	$3.2M-0.5%	$3.2M
Operating Income	-$170.6M	N/A	-$4.9M+6.8%	-$5.2M+28.4%	-$7.3M	N/A	-$7.8M-0.5%	-$7.8M
Interest Expense	N/A	N/A	$6K-40.0%	$10K-23.1%	$13K	N/A	$21K-12.5%	$24K
Income Tax	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$170.2M	N/A	-$4.6M+7.4%	-$4.9M+28.1%	-$6.9M	N/A	-$7.3M-1.6%	-$7.1M
EPS (Diluted)	$-131.45	N/A	$-3.62+7.4%	$-3.91	$-0.27	N/A	$-5.77-1.4%	$-5.69

SNSE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$22.9M-49.5%	$45.4M-39.0%	$74.4M-37.2%	$118.4M-22.7%	$153.2M+615.1%	$21.4M
Current Assets	$21.5M-48.7%	$41.9M-37.7%	$67.3M-38.1%	$108.6M-26.9%	$148.5M+639.9%	$20.1M
Cash & Equivalents	$8.7M-13.3%	$10.0M-23.2%	$13.0M-26.9%	$17.8M+148.6%	$7.2M-56.9%	$16.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.3M-38.2%	$7.0M-26.4%	$9.5M-36.7%	$15.0M+123.0%	$6.7M-91.4%	$77.9M
Current Liabilities	$4.3M-22.0%	$5.4M-3.5%	$5.6M-37.8%	$9.1M+85.4%	$4.9M+1.2%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$567K
Total Equity	$18.6M-51.6%	$38.4M-40.8%	$64.9M-37.2%	$103.4M-29.4%	$146.5M+359.6%	-$56.4M
Retained Earnings	-$283.1M-8.0%	-$262.1M-13.0%	-$231.9M-17.2%	-$197.8M-32.6%	-$149.2M-32.7%	-$112.4M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$205.4M+796.8%	$22.9M-17.0%	$27.6M-13.2%	$31.8M-17.0%	$38.3M-15.6%	$45.4M-14.8%	$53.3M-10.9%	$59.8M
Current Assets	$204.2M+849.6%	$21.5M-16.6%	$25.8M-12.8%	$29.6M-17.1%	$35.7M-14.9%	$41.9M-12.8%	$48.1M-10.8%	$53.9M
Cash & Equivalents	$152.3M+1657.3%	$8.7M-17.9%	$10.6M-15.9%	$12.6M+27.1%	$9.9M-1.2%	$10.0M-47.8%	$19.1M+60.9%	$11.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$342.7M+7850.5%	$4.3M-5.9%	$4.6M+2.5%	$4.5M-28.9%	$6.3M-9.9%	$7.0M-6.7%	$7.5M-1.7%	$7.6M
Current Liabilities	$14.2M+233.8%	$4.3M-4.2%	$4.4M+14.5%	$3.9M-25.9%	$5.2M-4.0%	$5.4M+0.1%	$5.4M+9.9%	$4.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$137.3M-838.4%	$18.6M-19.2%	$23.0M-15.8%	$27.3M-14.6%	$32.0M-16.7%	$38.4M-16.1%	$45.8M-12.3%	$52.2M
Retained Earnings	-$453.4M-60.1%	-$283.1M-1.7%	-$278.4M-1.7%	-$273.9M-1.8%	-$268.9M-2.6%	-$262.1M-3.1%	-$254.3M-2.9%	-$247.0M

SNSE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$20.5M+17.1%	-$24.7M+23.0%	-$32.0M+17.9%	-$39.0M-29.0%	-$30.3M-70.9%	-$17.7M
Capital Expenditures	$16K-89.0%	$146K-18.9%	$180K-43.9%	$321K-84.2%	$2.0M+68.0%	$1.2M
Free Cash Flow	-$20.5M+17.5%	-$24.8M+22.9%	-$32.2M+18.2%	-$39.3M-21.9%	-$32.3M-70.7%	-$18.9M
Investing Cash Flow	$19.8M-11.9%	$22.4M-41.6%	$38.4M-23.1%	$49.9M+134.9%	-$143.1M-10100.9%	-$1.4M
Financing Cash Flow	-$645K+18.0%	-$787K+93.0%	-$11.2M-3793.0%	-$287K-100.2%	$163.9M+362.4%	$35.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$10.4M	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$10.7M-177.8%	-$3.9M-7.8%	-$3.6M+39.3%	-$5.9M+16.7%	-$7.1M-22.5%	-$5.8M-5.9%	-$5.5M+5.6%	-$5.8M
Capital Expenditures	$6K	$0	$0-100.0%	$16K	$0	$0	$0-100.0%	$109K
Free Cash Flow	-$10.7M-177.9%	-$3.9M-7.8%	-$3.6M+39.5%	-$5.9M+16.5%	-$7.1M-22.5%	-$5.8M-5.9%	-$5.5M+7.3%	-$5.9M
Investing Cash Flow	-$31.4M-1610.6%	$2.1M+19.4%	$1.7M-80.1%	$8.8M+21.8%	$7.2M+328.2%	-$3.2M-124.4%	$12.9M+87.0%	$6.9M
Financing Cash Flow	$185.8M+167510.8%	-$111K+27.0%	-$152K+9.5%	-$168K+21.5%	-$214K-10.3%	-$194K+4.9%	-$204K-13.3%	-$180K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SNSE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-113.4%-34.9pp	-78.6%-26.0pp	-52.5%-5.6pp	-47.0%-21.9pp	-25.1%	N/A
Return on Assets	-92.1%-25.6pp	-66.5%-20.6pp	-45.9%-4.8pp	-41.0%-17.0pp	-24.0%+69.8pp	-93.8%
Current Ratio	5.06-2.6	7.70-4.2	11.92-0.1	11.98-18.4	30.38+26.2	4.16
Debt-to-Equity	0.23+0.1	0.18+0.0	0.150.0	0.14+0.1	0.05+0.1	-0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-19.9%-1.8pp	-18.1%+3.4pp	-21.5%	N/A	-15.8%-2.2pp	-13.7%
Return on Assets	-82.9%	N/A	-16.6%-1.0pp	-15.5%+2.4pp	-17.9%	N/A	-13.6%-1.7pp	-11.9%
Current Ratio	14.39+9.3	5.06-0.8	5.81-1.8	7.64+0.8	6.82-0.9	7.70-1.1	8.84-2.1	10.90
Debt-to-Equity	-2.50-2.7	0.23+0.0	0.20+0.0	0.16-0.0	0.20+0.0	0.18+0.0	0.16+0.0	0.15
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Marker Therapeut MRKR

$23.2M

Leap Therapeutic LPTX

$116.1M

Adaptimmune Therapeutics Plc ADAP

$14.6M

Phio Pharmaceuticals Corp PHIO

$12.5M

Xtl Biopharmaceu XTLB

$6.4M

Frequently Asked Questions

Is Sensei Biotherapeutics, Inc. profitable?

No, Sensei Biotherapeutics, Inc. (SNSE) reported a net income of -$21.1M in fiscal year 2025.

What is Sensei Biotherapeutics, Inc.'s EBITDA?

Sensei Biotherapeutics, Inc. (SNSE) had EBITDA of -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sensei Biotherapeutics, Inc.'s return on equity (ROE)?

Sensei Biotherapeutics, Inc. (SNSE) has a return on equity of -113.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sensei Biotherapeutics, Inc.'s free cash flow?

Sensei Biotherapeutics, Inc. (SNSE) generated -$20.5M in free cash flow during fiscal year 2025. This represents a 17.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sensei Biotherapeutics, Inc.'s operating cash flow?

Sensei Biotherapeutics, Inc. (SNSE) generated -$20.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sensei Biotherapeutics, Inc.'s total assets?

Sensei Biotherapeutics, Inc. (SNSE) had $22.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sensei Biotherapeutics, Inc.'s capital expenditures?

Sensei Biotherapeutics, Inc. (SNSE) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Sensei Biotherapeutics, Inc. have outstanding?

Sensei Biotherapeutics, Inc. (SNSE) had 1M shares outstanding as of fiscal year 2025.

What is Sensei Biotherapeutics, Inc.'s current ratio?

Sensei Biotherapeutics, Inc. (SNSE) had a current ratio of 5.06 as of fiscal year 2025, which is generally considered healthy.

What is Sensei Biotherapeutics, Inc.'s debt-to-equity ratio?

Sensei Biotherapeutics, Inc. (SNSE) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sensei Biotherapeutics, Inc.'s return on assets (ROA)?

Sensei Biotherapeutics, Inc. (SNSE) had a return on assets of -92.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sensei Biotherapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Sensei Biotherapeutics, Inc. (SNSE) had $8.7M in cash against an annual operating cash burn of $20.5M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sensei Biotherapeutics, Inc.'s Piotroski F-Score?

Sensei Biotherapeutics, Inc. (SNSE) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sensei Biotherapeutics, Inc.'s earnings high quality?

Sensei Biotherapeutics, Inc. (SNSE) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Sensei Biotherapeutics, Inc. cover its interest payments?

Sensei Biotherapeutics, Inc. (SNSE) has an interest coverage ratio of -696.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Sensei Biotherapeutics, Inc.?

Sensei Biotherapeutics, Inc. (SNSE) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.